{"title":"Biocon为其胰岛素类似物在Mylan找到了新的合作伙伴","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1901","DOIUrl":null,"url":null,"abstract":"Mylan has formed a global collaboration with the Indian biotech Biocon to develop and commercialise biosimilar versions of three insulin analogues: Sanofi’s Lantus® (glargine), Eli Lilly’s Humalog® (lispro) and Novo Nordisk’s NovoLog® (aspart). Together these products generated combined net sales of approximately US$11.5 B in 2012. Biocon was in need of a global partner for its biosimilar insulin programmes, which until March 2012 were licensed to Pfizer. Biocon and Mylan have an existing collaboration for the development and commercialisation of five high-value generic biologics.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I2.1901\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mylan has formed a global collaboration with the Indian biotech Biocon to develop and commercialise biosimilar versions of three insulin analogues: Sanofi’s Lantus® (glargine), Eli Lilly’s Humalog® (lispro) and Novo Nordisk’s NovoLog® (aspart). Together these products generated combined net sales of approximately US$11.5 B in 2012. Biocon was in need of a global partner for its biosimilar insulin programmes, which until March 2012 were licensed to Pfizer. Biocon and Mylan have an existing collaboration for the development and commercialisation of five high-value generic biologics.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"33 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I2.1901\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I2.1901","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Biocon Finds a New Partner for its Biosimilar Insulin Analogues in Mylan
Mylan has formed a global collaboration with the Indian biotech Biocon to develop and commercialise biosimilar versions of three insulin analogues: Sanofi’s Lantus® (glargine), Eli Lilly’s Humalog® (lispro) and Novo Nordisk’s NovoLog® (aspart). Together these products generated combined net sales of approximately US$11.5 B in 2012. Biocon was in need of a global partner for its biosimilar insulin programmes, which until March 2012 were licensed to Pfizer. Biocon and Mylan have an existing collaboration for the development and commercialisation of five high-value generic biologics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
